

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE  
Curriculum Vitae

Date: 07/21/2018

Vincent Lo Re III, M.D., M.S.C.E.

Address: Center for Clinical Epidemiology and Biostatistics  
836 Blockley Hall  
423 Guardian Drive  
Philadelphia, PA 19104 USA

If you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have:  
none (U.S. citizen)

Education:

1992	B.S.	Georgetown University (Chemistry)
1997	M.D.	University of Pennsylvania (Medicine)
2005	M.S.C.E.	University of Pennsylvania (Pharmacoepidemiology)

Postgraduate Training and Fellowship Appointments:

1997-1998	Intern in Medicine, Hospital of the University of Pennsylvania
1998-2000	Resident in Medicine, Hospital of the University of Pennsylvania
2000-2001	Chief Medical Resident, Hospital of the University of Pennsylvania
2001-2003	Fellow in Infectious Diseases, Hospital of the University of Pennsylvania
2003-2007	Research Fellow in Pharmacoepidemiology and Infectious Diseases Epidemiology, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania

Military Service:

[none]

Faculty Appointments:

2007-2008	Instructor in Medicine and Epidemiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2008-2017	Assistant Professor of Medicine, University of Pennsylvania School of Medicine
2008-2017	Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2017-present	Associate Professor of Medicine, University of Pennsylvania School of Medicine

2017-present	Associate Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
--------------	--

Hospital and/or Administrative Appointments:

2003-present	Attending Physician, Infectious Diseases Section, Medicine Service, Philadelphia Veterans Affairs Medical Center
2004-present	Attending Physician, Infectious Diseases Division, Penn Presbyterian Medical Center
2010-present	Attending Physician, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
2015-present	Associate Director, NIGMS-funded T32 Pharmacoeconomics Training Grant, Perelman School of Medicine

Other Appointments:

2005-2008	Faculty-Fellow, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2008-present	Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2008-present	Member, Epidemiology and Biostatistics Graduate Group, Perelman School of Medicine, University of Pennsylvania
2014-2017	Co-Director HIV/Viral Hepatitis Coinfection Scientific Working Group, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania
2017-present	Co-Director, Clinical Core, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania

Specialty Certification:

2000	Internal Medicine
2003	Infectious Diseases
2005	Epidemiology

Licensure:

2000-present	Pennsylvania (MD-070718-L)
--------------	----------------------------

Awards, Honors and Membership in Honorary Societies:

1992	Phi Beta Kappa, Georgetown University
1992	Chemistry Achievement Award, Georgetown University
1993	Penn Geriatrics Scholarship, Edinburgh University, Edinburgh, Scotland
1999	Pfizer Resident Award for Outstanding Performance in Infectious Diseases
1999	Maurice F. Attie Junior Medical Resident Teaching Award

2000	Maurice F. Attie Senior Medical Resident Teaching Award
2001	"Penn Pearls" Medical Student Teaching Award
2001	Francis H. Sterling Award for Educational Excellence
2002	Robert Austrian Fellowship Award in Infectious Diseases
2005	George McCracken Infectious Disease Fellow Travel Grant, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
2005	Young Investigator Award, 13th Conference on Retroviruses and Opportunistic Infections
2006	Young Investigator Award, 14th Conference on Retroviruses and Opportunistic Infections
2006	George McCracken Infectious Disease Fellow Travel Grant, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
2007	Top 30% Reviewer, Annals of Internal Medicine
2008	Top 10% Reviewer, Annals of Internal Medicine
2008	Top 5% Reviewer, Clinical Infectious Diseases
2009	Top 10% Reviewer, Annals of Internal Medicine
2010	Clinical Infectious Diseases Award for Outstanding Reviews
2010	Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics
2011	Penn Department of Medicine Robert Austrian Award in Health Evaluation Research
2011	Poster of Distinction Award, Digestive Disease Week
2013	Fellow, International Society for Pharmacoepidemiology
2013	Leonard Berwick Memorial Teaching Award, Penn Medicine Award of Excellence, Perelman School of Medicine
2014	Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics
2014	Top 10% Reviewer, Annals of Internal Medicine
2016	2016 HIV Medicine Association Research Award, Infectious Diseases Society of America

Memberships in Professional and Scientific Societies and Other Professional Activities:

International:

2005-present	International AIDS Society (Member)
2006-present	International Society for Pharmacoepidemiology (Member 2006-Present; Membership Committee Member 2009-Present; Membership Committee Vice-Chair 2011-2013; Membership Committee Chair 2013-2014; Education Committee Member 2010-Present; Academic Council Member 2013-Present; Fellow 2013-Present; Strategic Planning Committee Member 2015-Present; Board of Directors 2015-2018)
2011	Health Research Board of Ireland: Clinical and Applied Biomedical Research, Infectious Diseases Study Section, Dublin, Ireland (Member)

- 2014-present International Conference on Pharmacoepidemiology & Therapeutic Risk Management Scientific Program Committee (Member 2014-Present; Newcomer Track Director 2014-Present; Scientific Program Chair 2019)
- National:
- 2000-present American College of Physicians (Member)
- 2001-present Infectious Diseases Society of America (IDSA) (Member 2001-Present; Fellow 2015-Present; Research Committee Member 2015-2018)
- 2004-present American Association for the Study of Liver Diseases (Member)
- 2005-present American College of Epidemiology (Member)
- 2005-present HIV Medicine Association (Member)
- 2005-present Society for Epidemiologic Research (Member)
- 2007-present Veterans Aging Cohort Study (VACS) (Member 2007-Present; Liver Core Member 2007-Present; Co-Chair Liver Core 2009-Present; Executive Committee Member 2010-Present; Publications Committee 2017-Present)
- 2010-present North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (Member Liver Disease Working Group, HIV/HBV Coinfection Lead 2014-present)
- 2011-2013 FDA Mini-Sentinel Severe Liver Injury Workgroup (Workgroup Leader 2011-2013)
- 2013 National Institutes of Health (Study Section Member, Special Emphasis Panel/Scientific Review Group ZAI1-SM-M-C1 Study Section)
- 2013-2015 US Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee (Member)
- 2014-present American Conference for the Treatment of HIV (Member, Program Committee; Co-Chair, HIV/Viral Hepatitis Program)
- 2015-2017 National Academies of Sciences, Engineering, and Medicine Committee for a National Strategy for the Elimination of Hepatitis B and C (Member)
- 2015-present US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (Member)
- 2015 US Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee (Ad Hoc Member, 2015)

- 2015 VA Healthcare Network Competitive Pilot Project Fund (Study Section Member)
- 2016 AIDS Clinical Trials Group (ACTG) Hepatitis External Advisory Committee (Member)
- 2017-present American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel (Member)
- 2017-present National Institutes of Health (Study Section Member, Special Emphasis Panel/Scientific Review Group ZRG1 AARR-E (83) S, "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection")
- 2017 US Food and Drug Administration (FDA) Drug Safety and Risk Management Advisory Committee (Ad Hoc Member, 2017)

Editorial Positions:

- 2002-2004 Editorial Advisory Board Member, JAMA, "On Call-Issues in Graduate Medical Education" Section
- 2002-2004 Editor, Infectious Diseases Hot Topics, Philadelphia: Hanley & Belfus, 2004
- 2005-present Peer Reviewer, Clinical Infectious Diseases
- 2005-present Peer Reviewer, Pharmacoepidemiology and Drug Safety
- 2005-present Peer Reviewer, Annals of Internal Medicine
- 2006-present Peer Reviewer, Alcoholism: Clinical and Experimental Research
- 2007-present Peer Reviewer, International Journal of Infectious Diseases
- 2007-present Peer Reviewer, Clinical Microbiology Reviews
- 2007-present Peer Reviewer, Gastroenterology
- 2008-present Peer Reviewer, HIV Clinical Trials
- 2009-2017 Associate Editor, Pharmacoepidemiology and Drug Safety
- 2009-present Peer Reviewer, BMC Infectious Diseases
- 2009-present Peer Reviewer, JAIDS
- 2009-present Peer Reviewer, Liver International
- 2010-2013 Associate Editor, BMC Infectious Diseases
- 2010-present Peer Reviewer, HIV Medicine
- 2010-present Peer Reviewer, BMC Gastroenterology
- 2010-present Peer Reviewer, European Journal of Gastroenterology and Hepatology
- 2011-present Peer Reviewer, Journal of Medical Virology
- 2011-present Peer Reviewer, British Journal of Clinical Pharmacology
- 2011-present Peer Reviewer, Hepatology
- 2011-present Peer Reviewer, Journal of Hepatology
- 2012-present Peer Reviewer, AIDS and Behavior
- 2013-present Peer Reviewer, AIDS
- 2013-present Peer Reviewer, Antiviral Therapy

2014-present	Peer Reviewer, Journal of Antimicrobial Chemotherapy
2014-present	Peer Reviewer, New England Journal of Medicine
2015-present	Peer Reviewer, The Lancet
2016-present	Peer Reviewer, Drug Safety
2017-present	Peer Reviewer, Proceedings of the National Academy of Sciences
2018-present	Regional Editor for the Americas, Pharmacoepidemiology and Drug Safety

Academic and Institutional Committees:

2000-2001	Chair, House Staff Committee, Hospital of the University of Pennsylvania
2000-2001	Member, Graduate Medical Education Committee, Hospital of the University of Pennsylvania
2006-2013	Member, Intern Selection Committee, Hospital of the University of Pennsylvania
2007-2009	Member, Fellowship Selection Committee, Division of Infectious Diseases, Department of Medicine Perelman School of Medicine, University of Pennsylvania
2008-present	Member, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2009-present	Member, Steering Committee, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
2011-present	Chair, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2011-present	Member, Special Programs in Education Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2012-present	Member, Curriculum Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2013	Member, Medical Student Research Paper Prize Committee, Perelman School of Medicine, University of Pennsylvania
2013-2016	Chair, Data Safety Monitoring Board, "A Placebo controlled trial of varenicline for smoking among those with HIV/AIDS" (R01 DA033681; PI, Robert A. Schnoll, PhD), Perelman School of Medicine, University of Pennsylvania
2014-present	Member, Infectious Diseases Research Group, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2014-present	Member, Gastroenterology and Hepatology Clinical Research Program, Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, Department of Medicine, University of Pennsylvania

2015	Search Committee Member, Academic Clinician and Epidemiologist, Good Shepherd Penn Partners, University of Pennsylvania
2017-present	Vice Chair, Reputation/Visibility Committee, Penn Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2017-present	Member, Research Advisory Committee, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

Major Academic and Clinical Teaching Responsibilities:

2005-2013	Lecturer, "Overview of Viral Hepatitis," Frontiers in Medicine Course for Fourth-Year Penn Medical Students
2006-2013	Course Co-Director, Clinical Investigator Toolbox elective rotation for 2nd and 3rd year Medical Residents, Hospital of the University of Pennsylvania
2006-present	Lecturer, "Challenges in Conducting Epidemiologic Studies of HIV/Viral Hepatitis Coinfection," Epidemiological Methods in Infectious Diseases EPID 656
2007-present	Attending Physician, Penn Center for Viral Hepatitis, Penn Presbyterian Medical Center, 1 session/week
2007-present	Attending Physician, Infectious Diseases Consultation Service, Penn Presbyterian Medical Center, 4 weeks/year
2008-2009	Faculty Mentor, Jennifer Lin, MD, Penn Medical Resident
2008-2010	Faculty Mentor, Michelle DallaPiazza, MD, Penn Medical Resident
2008-2010	Faculty Mentor, Omowunme Aibana, MD, Penn Medical Student Penn Scholarly Pursuit Research; Brigham and Women's Hospital Medical Resident
2008-2009	Junior Faculty Mentor and Research Advisor, Adeel A. Butt, MD, MSc, Assistant Professor of Medicine Infectious Diseases, University of Pittsburgh Medical Center
2008-2013	Infectious Diseases Fellows Educational Lecture Series, "Management of Chronic HCV Infection in HIV"
2008-2015	Faculty Mentor, Alexis Ogdie-Beatty, MD, Penn Medical Resident; Penn Rheumatology Fellow; Assistant Professor of Medicine Rheumatology and Epidemiology, Perelman School of Medicine
2008-2011	Faculty Mentor, Carrie L. Kovarik, MD, Assistant Professor of Dermatology, Perelman School of Medicine
2009-2018	Course Director and Instructor, Biostatistics for Epidemiologic Methods Laboratory EPID 526-527, 24 weeks, 1.5 hour lectures per week
2009-2012	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Jeffrey S. Hafkin, MD, MSCE, Infectious Diseases Fellow, 1 hour per week for 36 months, 144 contact hours, resulted in abstract at CROI and Journal publication

- 2009-2010 Faculty Mentor and Research Advisor, Jessica Volk, MD 4th year Penn Medical Student, 3 hours per week for 10 months, 120 contact hours resulted in Penn FOCUS Grant; 2 abstracts presented at 2011 CROI conference; Co-Author Journal publication
- 2009-2010 Faculty Mentor, Valerianna K. Amorosa, MD Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine
- 2009-2012 Faculty Mentor, Zachariah Dorey-Stein, Temple University Post-Baccalaureate Premedical Program Student
- 2010-2013 Lecturer, "Effect of HCV on Bone Density and Fractures," Frontiers in Medicine Course for Fourth-Year Penn Medical Students
- 2010-2015 Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Hillary Hernandez-Trujillo, MD, MSCE, CHOP Immunology Fellow
- 2010-2011 Junior Faculty Mentor and Research Advisor, Ingi Lee, MD, MSCE, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine, 3 hours per week for 12 months, 144 contact hours, resulted in Oral Abstract Presentation in 2011 American Transplant Congress and Journal Publication
- 2010-present Faculty Mentor, Kimberly A. Forde, MD, MHS, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology
- 2010 Presenter, "Complications of HIV/HCV Coinfection: Effect of HCV on Bone Density and Fractures," Penn Center for Viral Hepatitis Research Symposium
- 2011-present Lecturer, "Challenges in Conducting Cohort Studies to Examine the Epidemiology of Hepatitis C Virus Infection," GI Epidemiology (EPID 658)
- 2011-2015 Faculty Mentor, David S. Goldberg, MD, MSCE, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology
- 2011-2015 Co-Investigator on F31 Application, Lesley S. Park, PhD, Yale University PhD in Epidemiology Student
- 2012-2016 Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Dana D. Byrne, MD, MSCE; Penn Infectious Diseases Fellow
- 2012 Presenter, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients," Penn Center for Viral Hepatitis Research Symposium
- 2012-2014 Faculty Mentor, Joseph K. Lim, MD, Assistant Professor of Medicine Gastroenterology, Yale School of Medicine research project: "Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients;" 2 hours per week for 24 months, 48 contact hours
- 2012-2016 Master of Science in Clinical Epidemiology Thesis Committee Member, Beth Floyd, MD, MSCE; Penn Gastroenterology Fellow



- 2013-2016 Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Charitha Gowda, MD, MPH, MSCE; Penn Infectious Diseases Fellow; Awarded CROI Young Investigator Award and Penn Infectious Diseases Division Robert Austrian Research Award, both in 2016, in recognition of Master's thesis research accomplishments. Thesis featured in special topical collection on HIV and Hepatitis C Co infection collated for the 9th International AIDS Society Conference on HIV Science 2017.
- 2013-2014 Faculty Mentor, Baligh Yehia, MD, MPP, MSHP, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine
- 2013 Viral Hepatitis Grand Rounds, "Bone Disease with Hepatitis C Virus Infection and HIV/Hepatitis C Coinfection"
- 2013 Infectious Diseases Grand Rounds, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients"
- 2013-present Lecture to Penn medical residents, "Management of Chronic HCV in HIV"
- 2014-2017 Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Tatyana Kushner, MD, MSCE; Penn Gastroenterology Fellow; Awarded 2017 NIH Loan Repayment Program, Frank Brooks Research Award by Penn Gastroenterology Division, and 48th Annual Komarov Prize for GI Research in recognition of Master's thesis research accomplishments. 2018 AASLD Clinical, Translational and Outcomes Research Award in Liver Diseases for postdoctoral research.
- 2014 Viral Hepatitis Grand Rounds, "HIV/Hepatitis C Virus Coinfection: Interactive Cases"
- 2014 Presenter, "Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women," Penn Center for AIDS Annual Research Retreat
- 2014-2016 Faculty Mentor, M. Elle Saine, MA, Penn Pre-Health Post-Baccalaureate Program Student, Penn Medical Student
- 2014-2017 Faculty Mentor and Doctoral Thesis Committee Member, Bret Zeldow, Penn PhD in Biostatistics Student, weekly meetings
- 2014 Infectious Diseases Grand Rounds, "Predicting Risk of End-Stage Liver Disease in HIV/HCV Patients: Can We Forecast Liver Complications?"
- 2014 Infectious Diseases Grand Rounds, "Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women"
- 2015-present Lecturer, "Use of Automated Databases for Comparative Effectiveness Research," Methods in Patient-Centered Outcomes and Effectiveness Research EPID 624
- 2015 Viral Hepatitis Grand Rounds, "Epidemiology and Treatment of HIV/HCV Coinfection: 2015 Update"

2015	Infectious Diseases Grand Rounds, "Drug-Induced Acute Liver Failure"
2016	Center for Clinical Epidemiology and Biostatistics Weekly Seminar, "Pharmacoepidemiology of Drug-Induced Acute Liver Failure"
2016	Division of General Internal Medicine Grand Rounds, "Epidemiology of HIV/Viral Hepatitis Coinfection"
2016-present	Master of Science in Clinical Epidemiology Thesis Committee Member, Dagan E. Coppock, MD; Penn Infectious Diseases Fellow
2016-present	Course Director, Biostatistics for Epidemiologic Methods Lectures EPID 526-527, 24 weeks, 3.0 hour lectures per week
2016-2017	Faculty Mentor, Mona Gizaw, Penn Undergraduate Student, Penn Access Summer Scholars Program
2016-present	Faculty Mentor, Jessie Torgersen, MD; Penn Infectious Diseases Fellow; Awarded CROI Young Investigator Award in 2016 and 2017 in recognition of research accomplishments and Highlighted Poster Presentation at the 16th International Conference in Malignancies in HIV/AIDS.
2017	Division of Gastroenterology Interdisciplinary Grand Rounds, "Hepatitis B Reactivation"
2017-present	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Joanna M. Rhodes, MD; Penn Hematology and Oncology Fellow
2017-present	Doctoral Thesis Committee Member, Wei (Vivian) Wang, University of Florida PhD in Pharmacoepidemiology Student
2017-present	Faculty Mentor and Doctoral Thesis Committee Member, M. Elle Saine, Penn MD/PhD in Epidemiology Student, weekly meetings. Awarded Penn Leonard Davis Institute 2018 Pilot Grant.

Lectures by Invitation (Last 5 years):

Feb, 2013	"Validation of Clinical Outcomes in Electronic Data Sources" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
Feb, 2013	"Validity of Diagnostic Codes to Identify Cases of Severe Acute Liver Injury in the U.S. Food and Drug Administration (FDA) Mini-Sentinel Distributed Database" U.S. Food and Drug Administration Monthly Webinar
Mar, 2013	"Clarifying the Classifications of Liver Injury and Disease in Electronic Data Sources" FDA Drug-Induced Liver Injury Conference, University of Maryland, East Hyattsville, MD
Apr, 2013	"Epidemiologic Methods to Evaluate for Antiretroviral-Induced Liver Injury" Pennsylvania/MidAtlantic AIDS Education and Training Center, Drexel University, Philadelphia, PA
Aug, 2013	"Methodological Challenges in Evaluating Drug-Induced Liver Injury in Pharmacoepidemiology Data" 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada

- Aug, 2013 "Validation of Clinical Outcomes in Electronic Data Sources" 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada
- Aug, 2013 "How to Teach Biostatistics to Nonstatisticians in Biomedical Environments" Joint Statistical Meeting 2013, Montreal, Canada
- Oct, 2013 "HIV-HCV Co-Infection Studies in the Veterans Aging Cohort Study" Canadian HIV Trials Network Scientific Workshop, Montreal, Canada
- May, 2014 "End-Stage Liver Disease Ascertainment and Validation Using Cohort Data" Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS) Semi-Annual Meeting, Rockville, MD
- Sep, 2014 "New Treatments for HCV: Moving to an Interferon Free World" 54th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC
- Oct, 2014 "Incidence of Drug-Induced Acute Liver Failure: A Population-Based Study" 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan
- Oct, 2014 "Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women" ID Week 2014, Philadelphia, PA
- Oct, 2014 "Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection" 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan
- Oct, 2014 "Validation of Clinical Outcomes in Electronic Data Sources" 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan
- Dec, 2014 "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients" Pennsylvania Department of Health Research Forum, Harrisburg, PA
- May, 2015 "HIV/Hepatitis C Virus Epidemiology: 2015 Update" American Conference for the Treatment of HIV 2015, Dallas, TX
- Jun, 2015 "Drug-Induced Acute Liver Failure in an Integrated Health System" Works in Progress Conference, VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT
- Aug, 2015 "Risk of Acute Liver Failure in Patients with Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model" 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA
- Aug, 2015 "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA

- Nov, 2015 "Incidence and Determinants of Denial of Direct-Acting Antiviral Treatment for Chronic HCV Infection by Insurance Type During the First 6 Months of the Modern HCV Treatment Era" The Liver Meeting 2015, San Francisco, CA
- Mar, 2016 "Best Practices for Case Identification in U.S. Automated Claims Databases" International Society for Pharmacoepidemiology Webinar
- Apr, 2016 "HIV/Hepatitis C Virus Coinfection Management" American Conference for the Treatment of HIV 2016, Dallas, TX
- Jun, 2016 "Eliminating the Problem of Hepatitis B and C in the United States" Centers for Disease Control and Prevention/Health Resources and Services Administration Advisory Committee Meeting on HIV, Viral Hepatitis and STD Prevention and Treatment, Atlanta, GA
- Aug, 2016 "Risk of hepatic decompensation with cumulative mitochondrial toxic nucleoside analogue use in HIV/hepatitis C coinfection" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Aug, 2016 "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Aug, 2016 "Final results of a large multi-national postmarketing safety study evaluating use of the oral anti-diabetic drug saxagliptin and risk of five outcomes" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Nov, 2016 "Case Studies in HIV and HCV Coinfection" American Conference for the Treatment of HIV Special Training for Effective Providers in HIV Webinar
- Nov, 2016 "Use of Automated Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
- Nov, 2016 "Validation of Clinical Outcomes in Electronic Data Sources" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
- Dec, 2016 "Incidence and Risk Factors for End-Stage Liver Disease Among HIV/Hepatitis C-Coinfected Patients" University of Florida Department of Pharmaceutical Outcomes and Policy Grand Rounds, Gainesville, FL
- Dec, 2016 "HIV and Aging Mechanisms for Hepatocellular Cancer" Veterans Aging Cohort Study Scientific Meeting, Washington, DC
- Dec, 2016 "Challenges in Access to Direct-Acting Antiviral Therapy for HCV: A Threat to HCV Elimination." Pennsylvania Department of Health Research Forum, Harrisburg, PA
- Mar, 2017 "Use of Automated Databases for Clinical Epidemiologic Research" University of Botswana Research Seminar, Gaborone, Botswana

- Mar, 2017 "Epidemiology and Management of Chronic Hepatitis B in HIV" Botswana HIV Clinicians Society Meeting, University of Botswana, Gaborone, Botswana
- Mar, 2017 "Drug-Induced Acute Liver Failure: A Concern for Clinicians?" Department of Medicine Seminar, Princess Marina Hospital, Gaborone, Botswana
- Apr, 2017 "HIV/Hepatitis C Virus Coinfection Management" American Conference for the Treatment of HIV 2017, Dallas, TX
- Apr, 2017 "A National Strategy for the Elimination of Hepatitis B and C in the US: Eliminating Hepatitis C Morbidity and Mortality" CDC Foundation Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States, Atlanta, GA
- Aug, 2017 "How to Manage a Pharmacoepidemiology-Based Research Team" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada
- Aug, 2017 "How to Manage a Pharmacoepidemiology-Based Research Team" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal Canada
- Aug, 2017 "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada
- Oct, 2017 "Use of Automated Databases for Pharmacoepidemiology Research" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia
- Oct, 2017 "A National Strategy for the Elimination of Hepatitis B and C in the US" Philadelphia Department of Public Health, Philadelphia, PA
- Oct, 2017 "Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia
- Oct, 2017 "Evaluation of Clinical Outcomes in Automated Pharmacoepidemiology Databases" 10th Asian Conference on Pharmacoepidemiology, University of Queensland, Brisbane, Australia
- Nov, 2017 "Use of Automated Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
- Jun, 2018 "Evaluating Drug Exposure and Outcomes in Pharmacoepidemiology Databases" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Confounding and Bias in Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia

Jun, 2018	"Protocol Development for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Jun, 2018	"Use of Automated Databases for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Jun, 2018	"Determinants of Hepatocellular Carcinoma Among HIV-Infected Patients" Works in Progress Conference, VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT
Jun, 2018	"Statistical Test Selection in Epidemiologic Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Jun, 2018	"Overview of Pharmacoepidemiology Research Methods" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Jun, 2018	"Cohort Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Jun, 2018	"Case-Control Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
Aug, 2018	"How to Manage a Pharmacoepidemiology-Based Research Team" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic
Aug, 2018	"Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic
Sep, 2018	"Epidemiology of End-Stage Liver Disease and Hepatocellular Carcinoma in HIV-Infected Persons" HIV and Liver Disease 2018 Meeting, Moran, WY
Oct, 2018	"Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China
Oct, 2018	"Evaluation of Clinical Outcomes in Automated Pharmacoepidemiology Databases" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China
Oct, 2018	"Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China

Organizing Roles in Scientific Meetings:

Sep, 2010	Organizer and Moderator, "Therapies for Viral Hepatitis," Scientific Symposium, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Boston, MA
-----------	---

- Aug, 2013 Organizer and Moderator "Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources," Symposium 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Montreal, Canada
- Sep, 2014 Moderator "Hepatitis and CMV: New and Noteworthy," Oral Abstract Session, 54th Interscience Conference on Antimicrobial Agents and Chemotherapy  
Washington, DC
- Oct, 2014 Moderator "World War V: Viruses and Vaccines," Oral Abstract Session, 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Taipei, Taiwan
- May, 2015 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Ronald D. Wilcox, MD, "Viral Hepatitis" American Conference for the Treatment of HIV 2015  
Dallas, TX
- Aug, 2015 Moderator "Pharmacoepidemiology of Anti-Infectives and Steroids" Oral Abstract Session, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Boston, MA
- Aug, 2015 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Boston, MA
- May, 2016 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Ronald D. Wilcox, MD, "HIV/Hepatitis C Virus Coinfection" American Conference for the Treatment of HIV 2016  
Dallas, TX
- Aug, 2016 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Dublin, Ireland
- Apr, 2017 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE, Margaret Hoffman-Terry, MD, and Ronald D. Wilcox, MD, "HIV/Viral Hepatitis Coinfection" American Conference for the Treatment of HIV 2017  
Dallas, TX
- Apr, 2017 Scientific Organizing Committee Member, CDC Foundation Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States  
Atlanta, GA

- Aug, 2017 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Montreal, Canada
- Aug, 2017 Moderator, "Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease" Oral Abstract Session, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Montreal, Canada
- Oct, 2017 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Wei Zhou, PhD, "Use of Automated Databases for Pharmacoepidemiology Research" 10th Asian Conference on Pharmacoepidemiology  
University of Queensland, Brisbane, Australia
- Jun, 2018 Organizer and Moderator, "Introduction to Pharmacoepidemiology" 4th Medicines Utilization Research in Africa (MURIA) Conference  
University of Namibia, Windhoek, Namibia
- Aug, 2018 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Prague, Czech Republic
- Oct, 2018 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Wei Zhou, PhD, "Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology  
Xi'an, China
- Aug, 2019 Chair, Scientific Program Committee, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management  
Philadelphia, PA

### Bibliography:

#### Research Publications, peer reviewed (print or other media):

1. Lo Re V 3rd, Gasink L, Kostman, JR, Leonard D, Gross R: Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs 18(8): 436-42, August 2004.
2. Ende A, Lo Re V 3rd, DiNubile MJ, Mounzer K: Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDs 20(2): 75-8, February 2006.
3. Bisson GP, Frank I, Gross R, Lo Re V 3rd, Strom J, Wang X, Mogorosi M, Gaolathe T, Ndwapi N, Friedman H, Strom BL, Dickinson D: Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 20(9): 1333-6, June 2006.



4. Lo Re V 3rd, Schutte-Rodin S, Kostman JR: Obstructive sleep apnea among HIV patients. Int J STD AIDS 17(9): 614-20, September 2006.
5. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander C, Harrigan R, Bangsberg R, Montaner J, Hogg R: A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 194(8): 1108-14, October 2006.
6. Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44(3): 315-20, March 2007.
7. Lo Re V 3rd, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol 60(3): 294-9, March 2007.
8. Lo Re V 3rd, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel B, Rennert H, Stieritz D, Putt M, Frank I, Strom BL: Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 44(3): 344-50, March 2007.
9. McComsey GA, Lo Re V 3rd, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I: Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 46(8): 1290-6, April 2008.
10. Lo Re V 3rd, Wertheimer B, Localio AR, Kostman J, Dockter J, Linnen J, Giachetti C, Tebas P, Frank I, Strom BL, Gross R: Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol 43(1): 32-6, September 2008.
11. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, Lo Re V 3rd: Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 10(1): 25-32, January-February 2009.
12. Lo Re V 3rd, Amorosa VK, Localio R, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R: Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 48(2): 186-93, January 2009.
13. Butt AA, Tsevat J, Leonard AC, Shaikh OS, McMahon D, Khan UA, Dorey-Stein Z, Lo Re V 3rd: Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 13(4): 449-55, July 2009.

14. Lo Re V 3rd, Haynes K, Forde K, Localio AR, Schinnar R, Lewis JD: Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 18(9): 807-14, September 2009.
15. Lo Re V 3rd, Guaraldi G, Leonard MB, Lin J, Orlando G, Squillace N, Rochira V, Giovanni C, Kostman JR, Tebas P: Viral hepatitis coinfection is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 23(16): 2191-8, October 2009.
16. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, Lo Re V 3rd: The influence of abacavir and other antiretroviral agents on virologic response to hepatitis C virus therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 15(1): 91-9, February 2010.
17. DallaPiazza M, Amorosa VK, Localio AR, Kostman JR, Lo Re V 3rd: Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 10: 116, May 13 2010.
18. Szep Z, Guaraldi G, Shah SS, Lo Re V 3rd, Ratcliffe SJ, Orlando G, Carli F, Rossi R, Rochira V, Tebas P: Vitamin D deficiency is associated with type 2 diabetes mellitus among HIV-infected patients. AIDS 25(4): 525-9, February 2011.
19. Garla V, Lo Re V 3rd, Dorey-Stein Z, Kidwai F, Scotch M, Womack J, Justice A, Brandt C: The Yale cTAKES Extensions for Document Classification: Architecture and application. J Am Med Inform Assoc 18(5): 614-20, May 2011.
20. Lo Re V 3rd, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Kidwai F, Brandt C, Dorey-Stein Z, Reddy KR, Justice AC: Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20(7): 689-99, July 2011.
21. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 155(6): 353-60, September 2011.
22. Lee I, Localio AR, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, Amorosa VK, Lo Re V 3rd: Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant 30(11): 1266-74, November 2011.

23. Park L, Tate J, Justice A, Lo Re V 3rd, Lim J, Bräu N, Brown S, Butt A, Gibert C, Goetz M, Rimland D, Rodriguez-Barradas M, Dubrow R: FIB-4 index predicts hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 20(12): 2512-7, December 2011.
24. Forde KA, Haynes K, Troxel A, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V 3rd: Risk of myocardial infarction associated with hepatitis C virus infection: A population-based cohort study. J Viral Hepat 19(4): 271-7, April 2012.
25. Goldberg DS, Lewis JD, Halpern SD, Weiner M, Lo Re V 3rd: Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 21(7): 765-9, July 2012.
26. Hernandez-Trujillo HS, Chapel H, Lo Re V 3rd, Notarangelo LD, Gathmann B, Grimbacher B, Boyle JM, Hernandez-Trujillo VP, Scalchunes C, Boyle ML, Orange JS: Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 169(1): 57-69, July 2012.
27. Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H, Strom BL: Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 21(11): 1202-15, November 2012.
28. Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR: Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 56(5): 1688-98, November 2012.
29. Raphael BA, Dorey-Stein ZL, Lott J, Amorosa VK, Lo Re V 3rd, Kovarik C: Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol 67(5): 962-8, November 2012.
30. Goldberg DS, Lewis JD, Halpern SD, Weiner M, Lo Re V 3rd: Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 22(1): 103-7, January 2013.
31. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 17(1): 94-103, January 2013.

32. Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd: Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol 47(5): 457-60, June 2013.
33. Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoabi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacepidemiol Drug Saf 8(22): 861-72, Aug 2013.
34. Edelman EJ, Gordon KS, Lo Re V 3rd, Skanderson M, Fiellin DA, Justice AC: Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf 22(12): 1352-6, December 2013.
35. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, Tate JP, Williams PL, Seage GR 3rd, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC: Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 58(5): 719-27, March 2014.
36. Keller SC, Momplaisir F, Lo Re V 3rd, Newcomb C, Liu Qing, Ratcliffe SJ, Long JA: Colorectal cancer incidence and screening in US Medicaid patients with and without HIV infection. AIDS Care 26(6): 716-22, March 2014.
37. Lo Re V 3rd, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.
38. Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat 21(4): 288-96, Apr 2014.
39. Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 58(10): 1449-58, May 2014.

40. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Prevalence of diagnosed chronic hepatitis B infection among US Medicaid enrollees, 2000-2007. Ann Epidemiol 24(6): 418-23, June 2014.
41. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol 61(2): 210-8, June 2014.
42. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd: The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLOS One 9(7): e101554, July 2014.
43. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T: Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis 59(7): 1027-31, October 2014.
44. Armah KA, Lim JK, Lo Re V 3rd, Baker J, Tracy R, Butt AA, Agan B, Rimland D, Justice AC, Freiberg MS: HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res 12(1): 50-59, December 2014.
45. Gowda C, Compher C, Amorosa VK, Lo Re V 3rd: Association between chronic hepatitis C virus infection and low muscle mass in U.S. adults. J Viral Hepat 21(12): 938-43, December 2014.
46. Cai B, Hennessy S, Lo Re V 3rd, Small DS: Epidemiologic research using probabilistic outcome definitions. Pharmacoepidemiol Drug Saf 24(1): 19-26, January 2015.
47. Butt AA, Yan P, Lo Re V 3rd, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team: Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 175(2): 178-85, February 2015.
48. Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, Lo Re V 3rd, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM, Moore RD: Ascertainment and verification of end stage renal and liver disease outcomes in the North America AIDS Cohort Collaboration on Research and Design. AIDS Res Treat 2015: 923194, February 2015.

49. Ogdie AR, Pang WG, Forde KA, Bhangle SD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy KR, Schumacher HR, Lo Re V 3rd: Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord 16(19): 93, April 2015.
50. Saine ME, Carbonari DM, Newcomb CW, Nezamzadeh MS, Haynes K, Roy JA, Cardillo S, Hennessy S, Holick CN, Esposito DB, Gallagher AM, Bhullar H, Strom BL, Lo Re V 3rd: Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol 16(2): 8, April 2015.
51. Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
52. Lo Re V 3rd, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Haynes K, Leidl KBF, Reddy KR, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 24(7): 676-83, July 2015.
53. Lo Re V 3rd, Kallan MJ, Tate J, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR: Predicting risk of end-stage liver disease in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. Open Forum Infect Dis 2(3): ofv109, July 2015.
54. Hernandez-Trujillo H, Orange JS, Roy JA, Wang Y, Newcomb CN, Liu Q, Hennessy S, Lo Re V 3rd: Validity of primary immunodeficiency disease diagnoses in United States Medicaid data. J Clin Immunol 35(6): 566-572, August 2015.
55. Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V 3rd, Justice AC, Sherman KE: Virologic response and hematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 22(9): 691-700, September 2015.
56. Carbonari DM, Saine ME, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd: Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf 24(9): 999-1003, September 2015.

57. Lo Re V 3rd, Lynn K, Stumm E, Long J, Nezamzadeh MS, Baker JF, Kapalko A, Mounzer K, Tebas P, Kostman JR, Leonard MB: Structural bone deficits in HIV/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected women. J Infect Dis 212(6): 924-33, September 2015.
58. Gowda C, McKittrick N, Kim D, Kappes R, Lo Re V 3rd, Tebas P: Obesity is not associated with impaired immune response to influenza vaccination in HIV-infected persons. AIDS Res Treat 2015: Article ID 653840, October 2015.
59. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Increased risk of hip fracture associated with dually-treated HIV/hepatitis B virus coinfection. J Viral Hepat 22(11): 936-47, November 2015.
60. Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KBF, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA: Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy's Law and a new prognostic model. Clin Gastroenterol Hepatol 13(13): 2360-8, December 2015.
61. Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 129(3): 283-91, e5, March 2016.
62. Rogal SS, Yan P, Rimland D, Lo Re V 3rd, Al-Rowais H, Fried L, Butt AA: Incidence and progression of chronic kidney disease after hepatitis C seroconversion: Results from ERCHIVES. Dig Dis Sci 61(3): 930-6, March 2016.
63. Bhattacharya D, Tseng CH, Tate JP, Lo Re V 3rd, Gibert C, Butt A, Brown S, Lim JK, Rodriguez-Barradas MC, Rimland D, Kaufman E, Justice AC, Goetz MB: Isolated hepatitis B core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection. J Acquir Immune Defic Syndr 72(1): e14-17, May 2016.
64. Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR: Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 14(7): 1035-4, July 2016.
65. Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas M, Fiellin LE, Bryant K, Justice AC, Fiellin DA: Hepatic safety of buprenorphine in HIV-infected and uninfected patients with opioid use disorder: The role of HCV infection. J Subst Abuse Treat 68: 62-7, September 2016.

66. Gowda C, Brown TT, Compher C, Forde KA, Kostman JR, Shaw P, Tien PC, Lo Re V 3rd: Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS 30(16): 2519-28, October 2016.
67. Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice AC, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.: Risk of end-stage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 63(9): 1160-7, November 2016.
68. Gowda C, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Reddy KR, Roy JA, Carey M, Liu J, Marks AR, Schneider JL, Corley DA, Lo Re V 3rd: Risk of acute liver injury with antiretroviral therapy by viral hepatitis status. Open Forum Infect Dis 4(2): ofx012, January 2017.
69. Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, Lo Re V 3rd: Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol 73(1): 115-123, January 2017.
70. Gowda C, Sheikh U, Maier A, Chang KM, Kaplan DE, Lo Re V 3rd, Amorosa VK: Identifying barriers and potential strategies to improve hepatocellular carcinoma surveillance for HBV-infected Veterans. Fed Pract 34 (Suppl 4): S20-29, June 2017.
71. Butt AA, Ren Y, Lo Re V 3rd, Taddei TH, Kaplan DE: Comparing Child-Pugh, MELD and FIB-4 to predict clinical outcomes in HCV-infected persons: Results from ERCHIVES. Clin Infect Dis 65(1): 64-72, July 2017.
72. Taylor BS, So-Armah, Tate JP, Marconi VC, Koethe J, Bedimo R, Butt AA, Gibert CL, Goetz MB, Rodriguez-Barradas MC, Womack JA, Gerschenson M, Lo Re V 3rd, Rimland D, Yin MT, Leaf D, Tracy RP, Justice AC, Freiberg MS: HIV and obesity comorbidity increases interleukin 6 but not soluble CD14 or D-dimer. J Acquir Immune Defic Syndr 75(5): 500-508, July 2017.
73. Lo Re V 3rd, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB, Strom BL: Post-authorization safety study of the DPP-4 inhibitor saxagliptin: A large-scale multi-national family of cohort studies of five outcomes. BMJ Open Diabetes Res Care 5: e000400, August 2017.



74. Coppock D, Zambo D, Moyo D, Tanthuma G, Chapman J, Lo Re V 3rd, Graziani A, Lowenthal E, Hanrahan N, Littman-Quinn R, Kovarik C, Albarracin D, Holmes JH, Gross R: Development and usability of a smartphone application for tracking antiretroviral medication refill data for human immunodeficiency virus. Methods Inf Med 56(5): 351-359, September 2017.
75. Byrne DD, Tate JP, Forde KA, Kostman JA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd: Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic hepatitis C virus infection status. Clin Infect Dis 65(9): 1542-50, October 2017.
76. Lo Re V 3rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Kostman JR, Gross R, Justice AC, Roy JA: Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf 26(10): 1172-1181, October 2017.
77. So-Armah KA, Lim JK, Lo Re V 3rd, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi V, Goetz MB, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS: FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology 66(4): 1286-1295, October 2017.
78. Kushner T, Shaw PA, Kalra A, Magaldi LN, Monpara P, Bedi G, Krok K, Centkowski S, Dalldorf K, D'Souza J, Haleboua-De Marzio D, Goldberg DS, Levine LD, Srinivas SK, Lewis JD, Forde KA, Lo Re V 3rd: Incidence, determinants, and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. Liver Int Page: In Press. November 2017.
79. Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, Lo Re V 3rd: Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf Page: In Press. November 2017.
80. Li DK, Ren Y, Fierer DS, Rutledge S, Saikh OS, Lo Re V 3rd, Simon T, Abou-Samra A, Chung RT, Butt AA: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology Page: In Press. December 2017.
81. Roy J, Lum KJ, Dworkin JD, Lo Re V 3rd, Daniels MJ: Bayesian nonparametric generative models for causal inference with missing at random covariates. Biometrics Page: In Press. February 2018.

82. Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün K, Gibert C, Lo Re V 3rd, Rimland D, Womack J, Wyatt CM, Tate JP: Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 32(6): 739-49, March 2018.
83. Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd: Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: A national specialty pharmacy cohort study. Open Forum Infect Dis 5(6): ofy076, June 2018.
84. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 67(6): 2244-2253, June 2018.
85. Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, Lo Re V 3rd: Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf Page: In Press. July 2018.

Research Publications, peer-reviewed reviews:

1. Lo Re V 3rd, Brennan PJ, Wadlin J, Weaver R, Nachamkin I: Infected branchial cleft cyst due to *Bordetella bronchiseptica* in an immunocompetent patient. J Clin Microbiol 39(11): 4210-2, November 2001.
2. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis due to *Angiostrongylus cantonensis* in a returned traveler: case report and review of the literature. Clin Infect Dis 33(9): e112-5, November 2001.
3. Lo Re V 3rd, Bellini LM: William of Occam and Occam's razor. Ann Intern Med 136(8): 634-5, April 2002.
4. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis due to *Gnathostoma spinigerum*. J Infect 45(2): 117-20, August 2002.
5. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis. Am J Med 114(3): 217-23, February 2003.
6. Lo Re V 3rd, Fishman NO, Nachamkin I: Recurrent catheter-related *Rhodotorula rubra* infection. Clin Microbiol Infect 9(8): 897-900, August 2003.
7. Lo Re V 3rd, Gluckman SJ: Prevention of malaria in travelers. Am Fam Phys 68(3): 509-14, August 2003.

8. Lo Re V 3rd, Fox KR, Ferrari VA, Scott CH, Kossev PM, Kostman JR: Hypereosinophilia associated with cardiac rhabdomyosarcoma. Am J Hematol 74(1): 64-7, September 2003.
9. Lo Re V 3rd, Gluckman SJ: Fever in the returned traveler. Am Fam Phys 68(7): 1343-50, October 2003.
10. Lo Re V 3rd, Occi JL, MacGregor RR: Identifying the vector of Lyme disease. Am Fam Phys 69(8): 1935-7, Apr 2004.
11. Lo Re V 3rd, Gluckman SJ: Travel immunizations. Am Fam Phys 70(1): 89-99, July 2004.
12. Lo Re V 3rd, Kostman JR: Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Reader 14(10): 555-7, 562, 565-71, October 2004.
13. Lo Re V 3rd, Kostman JR: Management of chronic hepatitis C. Postgrad Med J 81(956): 376-82, June 2005.
14. Samaha F, Ky B, Lo Re V 3rd: Type III hyperlipoproteinemia unmasked by HIV antiretroviral therapy. Am J Med 118(6): 691-2, June 2005.
15. Lo Re V 3rd, Bellini LM: William Pepper Jr, MD (1843-1898): portrait of a nineteenth-century medical educator. J Med Biogr 14(3): 169-77, August 2006.
16. Lo Re V 3rd, Strom BL: The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. Pharmacoepidemiol Drug Saf 16(7): 818-25, July 2007.
17. Dorey-Stein Z, Amorosa VK, Kostman JR, Lo Re V 3rd, Shannon RP: Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr 3: 111-4, March 2008.
18. Lo Re V 3rd, Kostman JR, Amorosa VK: Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 12(3): 587-609, August 2008.
19. Bedimo R, Maalouf NM, Lo Re V 3rd: Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS 11(3): 285-93, May 2016.
20. Taddei TH, Lo Re V 3rd, Justice AC: HIV, aging, and viral coinfections: Taking the long view. Curr HIV/AIDS Rep 13(5): 269-78, September 2016.

21. Midgard H, Weir A, Palmateer N, Lo Re V 3rd, Pineda JA, Macías J, Dalgard O: HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 65: S33-45, October 2016.
22. Gowda C, Lo Re V 3rd: Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep Page: In Press. January 2018.

Contributions to peer-reviewed research publications, participation cited but not by authorship:

1. Leake JA, Mosley DG, England B, Graham JV, Plikaytis BD, Ampel NM, Perkins BA, Hajjeh RA: Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996-1997. J Infect Dis 181: 1435-40, April 2000.

Research Publications, non-peer reviewed:

[none]

Abstracts (Last 3 years):

1. Gilmore J, Lynn K, Breen D, Trooskin S, Slim J, Scangarello N, Kingcade A, Hunyh K, Lo Re V 3rd, Kostman JR: Effectiveness of sofosbuvir/simeprevir for HIV/HCV patients in clinical practice. Conference on Retroviruses and Opportunistic Infections 2015, Seattle, WA February 2015 Notes: Abstract 645, Selected for Themed Discussion.
2. Klein MB, Althoff KN, Jing Y, Kirk G, Lo Re V 3rd, Kim N, Kitahata MM, Thio C, Silverberg M, Moore RD: Has modern ART reduced end-stage liver disease risk in HIV/hepatitis coinfection? Conference on Retroviruses and Opportunistic Infections 2015, Seattle, WA February 2015 Notes: Poster presentation Abstract 638.
3. Tate JP, Wherry EJ, Kostman JR, Bhattacharya D, Garcia-Tsao G, Gibert C, Lim JK, Rimland D, Justice A, Lo Re V 3rd: Impact of SVR on liver decompensation and hepatic fibrosis markers in HIV/HCV. Conference on Retroviruses and Opportunistic Infections 2015, Seattle, WA February 2015 Notes: Poster presentation Abstract 656.
4. Lo Re V 3rd, Zeldow B, Kallan M, Tate JP, Carbonari DM, Kostman JR, Strom BL, Gross R, Justice AC, Roy J: Risk of liver decompensation in HIV/hepatitis C virus coinfection associated with use of mitochondrial toxic nucleoside analogues. 19th International Workshop on HIV Observational Databases, Catania, Sicily March 2015 Notes: Poster presentation Abstract 167.

5. Edelman EJ, Tate JP, Gordon KS, Akgun KM, Gibert CL, Lo Re V 3rd, Rimland D, Womack JA, Wyatt C, Skanderson M, Justice AC: Is excess medication associated with mortality among HIV+ and uninfected patients? Society of General Internal Medicine 38th Annual Meeting, Toronto, Canada April 2015 Notes: Poster presentation Abstract 2199417.
6. Lo Re V 3rd, Carbonari DM, Haynes K, Forde KA, Goldberg DS, Lewis JD, Reddy KR, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Comparative risk of acute liver injury associated with oral azole antifungal drugs. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 2015 Notes: Poster presentation Abstract 1109.
7. Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl K, Reddy KRR, Nezamzadeh MS, Roy JA, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA : Risk of acute liver failure in patients with drug-induced hepatitis: Evaluation of Hy's law and a novel prognostic model. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 2015 Notes: Oral Abstract 766.
8. Saine ME, Carbonari DM, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd: A method to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 2015 Notes: Poster presentation Abstract 1089.
9. Saine ME, Carbonari DM, Newcomb CW, Roy JA, Haynes K, Wood J, Gallagher AM, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd: Concordance of hospitalizations within the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) among type 2 diabetes mellitus patients. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 2015 Notes: Poster presentation Abstract 1094.
10. Gowda C, Sheikh U, Maier A, Chang KM, Kaplan DE, Lo Re V 3rd, Amorosa VK: Identifying barriers and potential strategies to improve HCC surveillance for HBV-infected veterans. ID Week 2015, San Diego, CA October 2015 Notes: Poster presentation Abstract 52385.
11. Lo Re V 3rd, Gowda C, Urick PN, Halladay J, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Reddy KR, Kostman JR: Incidence and determinants of denial of direct-acting antiviral treatment for chronic HCV infection by insurance type during the modern HCV treatment era. The Liver Meeting 2015, San Francisco, CA November 2015 Notes: Late-Breaking Oral Abstract 5.

12. So-Armah K, Tate J, Lim JK, Lo Re V 3rd, Marconi V, Samet J, Gibert C, Leaf D, Butt AA, Goetz MB, Rimland D, Rodriguez-Barradas M, Budoff M, Chang CC, Justice AC, Freiberg M: Liver injury independently predicts incident cardiovascular disease risk. The Liver Meeting 2015, San Francisco, CA November 2015 Notes: Abstract 1488.
13. So-Armah K, Tate J, Lim JK, Lo Re V 3rd, Marconi V, Samet J, Gibert C, Leaf D, Butt AA, Goetz MB, Rimland D, Rodriguez-Barradas M, Budoff M, Chang CC, Justice AC, Freiberg M: Liver injury is associated with total cardiovascular disease, heart failure, stroke, coronary heart disease, and acute myocardial infarction including among those without viral hepatitis (B or C), HIV, alcohol abuse, and obesity. American Heart Association Scientific Sessions 2015, Orlando, FL November 2015 Notes: Oral Abstract 198.
14. Althoff KN, Justice AC, Eron JJ, Jacobson L, Kirk GD, Klein MB, Lo Re V 3rd, Napravnik S, Silverberg MJ, Moore R: Hepatitis B and C, alcohol, and CD4 drive end-stage liver disease in HIV+ adults. Conference on Retroviruses and Opportunistic Infections 2016, Boston, MA February 2016 Notes: Oral Abstract 150.
15. Gowda C, Brown TT, Compher C, Forde KA, Kostman JR, Shaw PA, Tien P, Lo Re V 3rd: Prevalence and risk factors of low muscle mass in HIV/viral hepatitis coinfection. Conference on Retroviruses and Opportunistic Infections 2016, Boston, MA February 2016 Notes: Poster presentation Abstract 609.
16. Justice AC, McGinnis KA, Tate J, Fiellin DA, Lo Re V 3rd, Jones J, Hahn JA, Bryant KJ: PEth improves detection of alcohol and associated mortality among HIV+/HCV+ Conference on Retroviruses and Opportunistic Infections 2016, Boston, MA February 2016 Notes: Poster presentation Abstract 554.
17. Park LS, Tate JP, Lo Re V 3rd, Butt AA, Gibert C, Goetz MB, Brown ST, Lim J, Rimland D, Rodriguez-Barradas MC, Justice AC, Dubrow R: Multiplicative interaction between HIV infection status and FIB-4 in prediction of hepatocellular carcinoma risk. American Association for Cancer Research Annual Meeting, New Orleans, LA April 2016 Notes: Poster presentation Abstract 4308.
18. Lo Re V 3rd, Carbonari DM, Newcomb CW, Saine ME, Roy JA, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Bhullar H, Gallagher AM, Esposito DB, Strom BL: Final results of a large multi-national postmarketing safety study evaluating use of the oral anti-diabetic drug saxagliptin and risk of five outcomes. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland August 2016 Notes: Oral Abstract 420.

19. Lo Re V 3rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Kostman JR, Gross R, Justice AC, Roy JA: Risk of hepatic decompensation with cumulative mitochondrial toxic nucleoside analogue use in HIV/hepatitis C coinfection. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland August 2016 Notes: Oral Abstract 813.
20. Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, Lo Re V 3rd: Methods to estimate days' supply within pharmacy data of The Health Improvement Network (THIN). 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland August 2016 Notes: ISPE Special Interest Group Poster Spotlight Session Abstract 94.
21. Byrne DD, Tate JP, Forde KA, Kostman JR, Roy JA, Lo Re V 3rd: The risk of acute liver injury with statin use in chronic hepatitis C virus infection. ID Week 2016, New Orleans, LA October 2016 Notes: Poster presentation Abstract 6009.
22. Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Corley DA, Tate JP, Justice AC, Lo Re V 3rd: Risk of acute liver injury with modern antiretroviral therapy. ID Week 2016, New Orleans, LA October 2016 Notes: Poster presentation Abstract 59479.
23. Kushner T, Shaw PA, Kalra A, Magaldi LN, Monpara P, Bedi G, Krok K, Centkowski S, D'Souza J, Dalldorf K, Haleboua-De Marzio D, Levine LD, Srinivas SK, Lewis JD, Goldberg DS, Forde KA, Lo Re V 3rd: Incidence, determinants, and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. The Liver Meeting 2016, Boston, MA November 2016 Notes: Poster presentation Abstract 2551162.
24. Marconi VC, So-Armah K, Tate JP, Lim JK, Lo Re V 3rd, Butt AA, Goetz MB, Rodriguez-Barradas M, Justice AC, Freiberg M: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV- individuals. Conference on Retroviruses and Opportunistic Infections 2017, Seattle, WA February 2017 Notes: Oral Abstract 986.
25. Torgersen J, So-Armah K, Freiberg M, Budoff M, Lim JK, Butt AA, Rodriguez-Barradas M, Justice AC, Kostman JK, Lo Re V 3rd: Prevalence and risk factors for hepatic steatosis in HIV+ persons. Conference on Retroviruses and Opportunistic Infections 2017, Seattle, WA February 2017 Notes: Poster presentation Abstract 333.
26. Li DK, Ren Y, Saikh OS, Fierer D, Lo Re V 3rd, Abou-Samra AB, Chung R, Butt AA: The incidence of hepatocellular carcinoma is not increased in individuals after treatment with interferon-free regimens: an ERCHIVES study. ID Week 2017, San Diego, CA October 2017 Notes: Poster presentation Abstract 64061.

27. Torgersen J, Carbonari DM, Kallan M, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Park L, Kidwai-Khan F, Taddei T, Justice AC, Lo Re V 3rd: Advanced stage of hepatocellular carcinoma is more common among HCV uninfected US Veterans. 16th International Conference on Malignancies in HIV/AIDS, Bethesda, MD October 2017 Notes: Poster presentation Abstract 03.
28. Li DK, Ren Y, Fierer DS, Rutledge S, Saikh OS, Lo Re V 3rd, Abou-Samra A, Chung RT, Butt AA: The incidence of hepatocellular carcinoma is not increased in individuals with chronic hepatitis C after SVR with interferon-free regimens compared with interferon-containing regimens: an ERCHIVES study. The Liver Meeting 2017, Washington DC. Oral Abstract 2767638, November 2017.
29. Torgersen J, Carbonari DM, Kallan M, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Park LS, Kidwai-Khan F, Taddei T, Justice A, Lo Re V 3rd: Impact of HIV and chronic HCV status on advanced HCC stage in Veterans. The Liver Meeting 2017, Washington DC November 2017 Notes: Poster presentation Abstract 1427.
30. Benson EA, Klein MB, Kitahata MM, Moore RD, Lo Re V 3rd, Horberg MA, Mayor A, Silverberg MJ, Kim HN, Eron JJ, Cachay ER, Hull M, Gange SJ, Althoff KN: Survival after end-stage liver disease in adults with HIV: Data from the NA-ACCORD. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 624.
31. Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick PN, Lo Re V 3rd: Increasing incidence of denial of DAA therapy for chronic HCV by insurance type. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 600.
32. Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Kitahata MM, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Hull M, Moore RD, Klein MB, Kim HN: Determinants of liver complications among HIV/hepatitis B-coinfected patients. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 620.
33. Park LS, Justice AC, Lo Re V 3rd, Mehta R, Carbonari D, Torgerson J, D'Addeo K, Richards KM, Zhang X, Taddei T: Tissue collection to examine HIV and HCV mechanisms for hepatocellular carcinoma. 22nd International Workshop on HIV and Hepatitis Observational Databases, Fuengirola, Spain March 2018 Notes: Poster presentation Abstract 63.



34. Torgersen J, Park LS, Taddei T, Carbonari DM, Kallan MJ, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Kidwai-Khan F, Justice A, Lo Re V 3rd: Presentation and outcome of biopsy-proven hepatocellular carcinoma by HIV status Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 226.

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. Lo Re V 3rd, Barton T, Feiner S: A pain in the back [Letter] N Engl J Med 344(6): 456, February 2001.
2. Lo Re V 3rd, Fishman NO: Recognition and management of anthrax [Letter] N Engl J Med 346(12): 943-5, March 2002.
3. Lo Re V 3rd, Kostman JR: Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C [Letter] Clin Infect Dis 38(12): 1789-90, June 2004.
4. Lo Re V 3rd: Economic analysis of hepatitis B screening and treatment. Clin Infect Dis 52(11): 1307-1309, June 2011.
5. Lo Re V 3rd, Reddy KR: Hepatobiliary complications of HIV. Handbook of Liver Disease, 3rd Edition. Friedman LS, Keeffe EB (eds.). Elsevier, 2012.
6. Lo Re V 3rd, Tate JP, Lim JK, Fiellin DA, Justice AC: Reply to Marcellin et al. Clin Infect Dis 59(8): 1192-3, October 2014.
7. Justice AC, Freiberg MS, Lo Re V 3rd: Should everyone aging with HIV take a statin? Lancet HIV 2(2): e36-e37, February 2015.
8. Lo Re V 3rd, Schuster M: Evaluating hepatitis B virus reactivation during solid tumor chemotherapy: Evidence to guide pretreatment hepatitis B screening and prophylaxis. Ann Intern Med 164(1): 64-65, January 2016.
9. National Academies of Sciences, Engineering, and Medicine. 2016: Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press April 2016 Notes: doi: 10.17226/23407.
10. Lo Re V 3rd, Forde KA, Lewis JD, Goldberg DS, Carbonari DM, Roy JA, Reddy KR, Sha D, Strom BL, Corley DA: Reply: Is Sensitivity the Key Measure to Predict Acute Liver Failure in Drug-Induced Liver Injury Patients? Clin Gastroenterol Hepatol 14(6): 918-919, June 2016 Notes: Is sensitivity the key measure to predict acute liver failure in drug-induced liver injury patients? [Letter]

11. Lo Re V 3rd: Extrahepatic complications of hepatitis C virus infection in HIV and the impact of successful antiviral treatment. Clin Infect Dis 64(4): 498-500, February 2017.
12. Lo Re V 3rd, Carbonari DM, Lewis JD, Roy JA, Corley DA.: Reply: Effects of Treatment with Azoles Are Overstated. Am J Med 130(8): e369, August 2017.
13. Lo Re V 3rd: Is moderate alcohol consumption safe for HIV/hepatitis C virus-coinfected women? Clin Infect Dis 65(12): 2057-59, November 2017.

Books:

1. Infectious Diseases Hot Topics. Lo Re V 3rd (eds.). Hanley & Belfus, 2004.

Alternative Media:

1. Lo Re V 3rd, Gluckman SJ: Eosinophilic meningitis. MD Consult Infectious Disease. MD Consult, April 2002.
2. Lo Re V 3rd: Principal agents of bioterrorism: recognition and management. Psychiatric Times 22(14): 40, December 2005.
3. Lo Re V 3rd: Addressing anticipated adherence problems prior to hepatitis C virus treatment. Hepatitis C Online (<http://www.hepatitisc.uw.edu>). August 2013.
4. Gowda C, Lo Re V 3rd: What's behind fatigue, elevated liver enzymes? The Philadelphia Inquirer June 2015 Notes: June 28, 2015.
5. Lo Re V 3rd: Access to Direct-Acting Antiviral Therapy for Chronic HCV: Any Progress? AGA Perspectives (<http://agaperspectives.gastro.org/>) November 2016.

Patents:

[none]